4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.03,7]tetradeca-1(10),3(7),5,8,11,13-hexaene hydrate

• ChemBase ID: 175821
• Molecular Formular: C40H38N4O7S
• Molecular Mass: 718.81732
• Monoisotopic Mass: 718.24612058
• SMILES: c12c(Nc3c(C(=N1)N1CCN(CC1)C)cc(s3)C)cccc2.c1ccc2c(c1)cc(c(c2Cc1c(c(cc2c1cccc2)C(=O)O)O)O)C(=O)O.O
• Canonical SMILES: OC(=O)c1cc2ccccc2c(c1O)Cc1c(O)c(cc2c1cccc2)C(=O)O.CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(s2)C.O
• InChI: InChI=1S/C23H16O6.C17H20N4S.H2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12;/h1-10,24-25H,11H2,(H,26,27)(H,28,29);3-6,11,19H,7-10H2,1-2H3;1H2
• InChIKey: ZIMCQJVMPKQQPB-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(10),3(7),5,8,11,13-hexaene hydrate
• IUPAC Traditional name: 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,^7]tetradeca-1(10),3(7),5,8,11,13-hexaene pamoic acid hydrate
• Synonyms: 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylic Acid compound with 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine Hydrate; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylate] Monohydrate; Olanzapine Pamoate Hydrate

Database IDs

• CAS Number: 221373-18-8
• PubChem SID: 164231731
• PubChem CID: 22995473

CALCULATED PROPERTIES

• Acid pKa: 2.3815763
• H Acceptors: 6
• H Donor: 4
• LogD (pH = 5.5): 0.5700001
• LogD (pH = 7.4): -0.95232564
• Log P: 6.0520287
• Molar Refractivity: 107.1698 cm^3
• Polarizability: 42.550995 Å^3
• Polar Surface Area: 115.06 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: false

DETAILS

Toronto Research Chemicals - O253775

A new Olanzapine pamoate formulation of a second-generation antipsychotic.

REFERENCES

• Davis, J., et al.: Arch. Gen. Psychiatry, 60, 553 (2003)
• Kahn, R., et al.: Lancet, 371, 1085 (2003)
• Lauriello, J., et al.: J. Clin. Psychiatry, 69, 790 (2003)